Physician profile
Alexandre Alexeyenko
NPI 1568464279
$769.12
in general payments reported to CMS, 2019-2025
15 companies · $241 in 2025
The $241 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $16.31 · 2021: $75.94 · 2022: $52.98 · 2023: $94.29 · 2024: $289 · 2025: $241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $624.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $623.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $231.54 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $170.35 | 2024-2025 | Jardiance, Synjardy |
| Eisai INC. | $51.55 | 2023-2024 | |
| Lilly USA, LLC | $48.58 | 2025 | Zepbound, Mounjaro, Jardiance |
| Abbvie INC. | $38.36 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $37.83 | 2023-2024 | Rexulti |
| Novo Nordisk INC | $36.40 | 2025 | Ozempic, Wegovy |
| Phathom Pharmaceuticals, INC. | $29.34 | 2024 | Voquezna |
| Lundbeck LLC | $25.49 | 2024 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $22.85 | 2021 | |
| Exact Sciences Corporation | $17.36 | 2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $17.12 | 2021 | |
| Glaxosmithkline, LLC. | $16.31 | 2020 | |
| Pfizer INC. | $13.37 | 2021 | |
| Echosens North America, INC. | $12.67 | 2025 | Fibroscan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexandre Alexeyenko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.